The goal of this study is to define basic molecular mechanisms underlying the regulation of exocrine pancreatic cell growth by novel TIEG and BTEB Sp1-like zinc finger proteins discovered by our laboratory during the last cycle of funding. Sp1-like proteins have recently elicited significant interest because of their role in regulating gene expression, normal morphogenesis, and neoplastic transformation. Our previous observations led us to discoveries in two important areas: 1) cell growth suppression and 2) transcriptional repression. Now, our preliminary data supports a unifying theme by which these two areas may be linked, namely studies on corepressor molecules for novel Sp-like proteins. We chose this focus because of its high potential for providing novel mechanistic information that can fuel advances in our field of study. Corepressors constitute a new and exciting area of research which recently exploded after the discovery of histone-deacetylases and chromatin remodeling machines in mammalian cells. Few corepressors are known for Sp1-like proteins and nothing is known on their role in the regulation of exocrine pancreatic cell growth. Thus the central hypothesis of this proposal is that the Sp1-like zinc finger transcriptional repressors, TIEGs and BTEBs, regulate gene expression and cell growth in exocrine pancreatic cells via the interaction with distinct corepressor complexes.
Our specific aims will test the following hypothesis:
Aim 1 : Multiple corepressor interactions participate in the repression mediated by the TIEG and BTEB proteins;
Aim 2 : The transcriptional repression activity of TIEG proteins is regulated by cell signaling via the modulation of repressor corepressor interactions:
and Aim 3 : TIEG and BTEB proteins modulate pancreatic cell growth in a corepressor-dependent manner. These experiments will use state-of-the-art cellular and molecular techniques for analyzing both transcriptional repression and cell growth. We believe that focusing on corepressors makes this proposal innovative, hypothesis-driven, highly focused, and biologically- and medically-relevant, taking into consideration our expertise, previous published work, and current preliminary data. We are optimistic that the successful completion of these studies will help to build a useful theoretical framework for better understanding morphogenetic pathways that are active in exocrine pancreatic cells and that help to maintain their homeostasis regulate morphogenesis and modulate neoplastic transformation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052913-07
Application #
6795523
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Serrano, Jose
Project Start
1998-09-25
Project End
2007-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
7
Fiscal Year
2004
Total Cost
$214,590
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Colón-Caraballo, Mariano; Torres-Reverón, Annelyn; Soto-Vargas, John Lee et al. (2018) Effects of histone methyltransferase inhibition in endometriosis. Biol Reprod 99:293-307
Lomberk, Gwen; Blum, Yuna; Nicolle, Rémy et al. (2018) Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun 9:1978
Seo, Seungmae; Mathison, Angela; Grzenda, Adrienne et al. (2018) Mechanisms Underlying the Regulation of HP1? by the NGF-PKA Signaling Pathway. Sci Rep 8:15077
Xiang, Xiaoyu; Wang, Yuanguo; Zhang, Hongbin et al. (2018) Vasodilator-stimulated phosphoprotein promotes liver metastasis of gastrointestinal cancer by activating a ?1-integrin-FAK-YAP1/TAZ signaling pathway. NPJ Precis Oncol 2:2
Bian, Benjamin; Bigonnet, Martin; Gayet, Odile et al. (2017) Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol Med 9:482-497
Zimmermann, Michael T; Urrutia, Raul A; Blackburn, Patrick R et al. (2017) Novel Pathogenic Variant in TGFBR2 Confirmed by Molecular Modeling Is a Rare Cause of Loeys-Dietz Syndrome. Case Rep Genet 2017:7263780
Zimmermann, Michael T; Urrutia, Raul; Oliver, Gavin R et al. (2017) Molecular modeling and molecular dynamic simulation of the effects of variants in the TGFBR2 kinase domain as a paradigm for interpretation of variants obtained by next generation sequencing. PLoS One 12:e0170822
Blackburn, Patrick R; Williams, Monique; Cousin, Margot A et al. (2017) A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation. Mol Genet Genomic Med 5:141-146
Cousin, Margot A; Zimmermann, Michael T; Mathison, Angela J et al. (2017) Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loeys-Dietz syndrome (LDS) impairs canonical TGF-? signaling. Cold Spring Harb Mol Case Stud 3:
Kalinec, Gilda M; Lomberk, Gwen; Urrutia, Raul A et al. (2017) Resolution of Cochlear Inflammation: Novel Target for Preventing or Ameliorating Drug-, Noise- and Age-related Hearing Loss. Front Cell Neurosci 11:192

Showing the most recent 10 out of 129 publications